1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Chemclin Diagnostics Co., Ltd. Class A

Chemclin Diagnostics Co., Ltd. Class A

SSSE:688468
6.01
CNY
+0.10
(+1.69%)
2.28BMarket Cap
Chemclin Diagnostics Co., Ltd. Class A
SSE:688468
(Shanghai Stock Exchange)

Recent

price

6.01

P/E

ratio

- -

div

yld

0.15%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.79
0.91
1.26
1.18
1.22
1.16
1.12
1.1
0.83
- -
Revenue per Share
-1.09
-1.06
0.39
0.33
0.37
0.38
0.37
0.32
0.11
- -
Basic EPS, GAAP
0.18
0.25
0.41
0.19
0.3
0.3
-0.32
0.15
0.06
- -
Free Cash Flow per Basic Share
- -
- -
0.12
0.3
- -
0.17
0.35
0.13
0.14
0.01
Dividend per Share
1.8
2.15
2.41
2.46
3.19
3.44
3.46
3.53
3.52
3.56
Book Value per Share
1.37
1.73
1.98
2
2.77
2.99
2.97
3.04
3.05
3.09
Tangible Book Value per Share
401
401
360
355
386
402
398
397
399
408
Basic Weighted Avg Shares
319
366
455
418
471
465
445
436
333
- -
Sales/Revenue/Turnover
-133.55
-114.01
32.77
30.08
31.35
31.97
33.19
28.85
13.99
- -
Operating Margin (%)
38
39
42
42
53
51
49
54
57
- -
Depreciation Expense
-435
-424
141
117
143
153
147
127
44
- -
Net Income, GAAP
- -
- -
11.93
13.6
11.98
13.95
11.28
7.86
11.86
- -
Effective Tax Rate (%)
-136.61
-115.9
30.92
27.98
30.32
32.8
33.09
29.13
13.2
- -
Profit Margin (%)
357
496
594
594
970
968
908
884
602
499
Working Capital
- -
- -
- -
7
13
2
228
224
183
179
LT Debt
647
775
867
887
1,279
1,381
1,389
1,416
1,411
1,426
Total Equity
- -
- -
17.03
13.3
12.88
10.69
9.64
7.5
2.64
- -
Return on Invested Capital (%)
- -
- -
17.12
13.26
13.03
11.35
9.8
8.02
3
- -
Return on Capital (%)
- -
-59.65
17.12
13.34
13.18
11.48
10.64
9.06
3.11
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
49
51
51
LT Borrowings
160
160
160
LT Finance Leases
23
21
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
401
401
401
Market Capitalization
2,944
2,956
2,282

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
762
743
656
Cash, Cash Equivalents & STI
407
389
396
Accounts Receivable, Net
13
9
11
Inventories
110
111
108
Total Current Liabilities
160
156
158
Payables & Accruals
- -
- -
- -
ST Debt
49
51
51
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.85%
-0.38%
Free Cash Flow
- -
-68.6%
-60.28%
Net Income, GAAP
- -
-10.75%
-65.44%
Sales/Revenue/Turnover
- -
-3.73%
-23.75%
Total Cash Common Dividend
- -
- -
2.83%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
111
114
118
93
436
2025
81
83
- -
72
333
2026
73
81
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.1
0.09
0.04
0.32
2025
0.04
0.02
- -
0.01
0.11
2026
0.02
0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.13
2025
- -
0.13
- -
- -
0.14
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Chemclin Diagnostics Co., Ltd. (688468.SS) develops, manufactures, and sells clinical chemiluminescence immunoassay diagnostic reagents and instruments. The company offers LiCA series products based on proprietary light-initiated chemiluminescence immunoassay technology, including reagents and automated analyzers such as LiCA 500, LiCA 800, and LiCA 1500 for infectious diseases including hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, and hepatitis E; tumor markers; thyroid hormones; reproductive endocrine hormones; cardiac markers; and inflammation markers; as well as CC series products based on enzymatic chemiluminescence for similar applications. It operates primarily in China with global aspirations, targeting clinical laboratories and healthcare providers. Founded in 2007 and headquartered in Beijing, the company listed on the Shanghai Stock Exchange STAR Market in April 2021 and maintains a strong focus on R&D, recognized as a national high-tech enterprise and "Little Giant" in specialized new fields. Recent developments include advancements in thyroid function testing collaborations, such as ongoing tripartite projects for FT3 and FT4 assays expected to complete in early 2025, alongside shareholder reductions by key investors like Hengqin Junlian Zhikang.